Vitality Watch

Dossier clinicaltrials trial early 12-nov-2026
Small or early-phase human trial or pilot study

LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment

Key claim: A 48-week trial is evaluating the safety, tolerability, and biomarker efficacy of the neuroprotective drug LM11A-31 in older adults living with HIV and mild neurocognitive impairment.

Abstract

HIV rapidly infects the nervous system resulting in chronic infection that persists even when blood HIV is undetectable. The resulting inflammation causes progressive neuronal damage leading to cognitive decline in up to 50% of people living with HIV. The damage to the nervous system is due in part to a loss of natural processes that protect the brain. There are currently no effective treatments. A novel new drug, LM11A-31, has been shown to restore the protective processes thereby shifting the balance from degenerative to protective activity. Beneficial effects have been seen in patients with Alzheimer’s disease and research indicates that it should have similar beneficial effects in people living with HIV. The proposed study will establish the safety and tolerability of LM11A-31 treatment in a small cohort of stable virally-suppressed participants with HIV and mild neurocognitive impairment. The focus will be on individuals 50-75 years of age who are most vulnerable for cognitive decline. To provide sufficient time to stabilize brain activity, participants will take tablets twice daily over a period of 48 weeks. The main focus of the trial will be on safety but will also be supplemented with exploratory characterization of biomarkers to confirm a reduction in degeneration as well as to provide early identification of individuals at risk for neurodegeneration. These studies are expected to show that LM11A-31 is safe to use in people living with HIV and to provide preliminary data indicating protection from neuronal damage and cognitive decline.

Why this matters

[human-rct — provisional trial-status classification only] This early trial extends LM11A-31 investigation into older adults living with HIV and mild neurocognitive impairment, with safety, tolerability, and biomarker effects under evaluation. The supplied finding contains no outcome results, so it does not establish safety, cognitive benefit, or longevity effects in this population; randomization also remains unspecified.

Source

Link

Briefing card

LM11A-31 Safety and Tolerability in Aging People Living With HIV and Neurocognitive Impairment
Stage: trial early · clinicaltrials · 12-nov-2026

If you are an older adult living with HIV and mild neurocognitive impairment, this trial is studying LM11A-31 in your population, but this finding reports no safety or benefit results.

A 48-week trial is evaluating the safety, tolerability, and biomarker efficacy of the neuroprotective drug LM11A-31 in older adults living with HIV and mild neurocognitive impairment.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07934186

build build 880 · 2bcef25 · 2026-11-18